Catalyst Pharmaceuticals Files 2024 10-K
Ticker: CPRX · Form: 10-K · Filed: 2025-02-26T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
Related Tickers: CPRX
TL;DR
Catalyst Pharma (CPRX) dropped its 2024 10-K. Full year financials and biz details inside.
AI Summary
Catalyst Pharmaceuticals, Inc. filed its 2024 10-K on February 26, 2025, reporting on its fiscal year ending December 31, 2024. The company, focused on pharmaceutical preparations, is headquartered in Coral Gables, Florida. Key financial details and operational highlights for the year are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Catalyst Pharmaceuticals' financial performance, strategic initiatives, and risk factors for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Catalyst faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-02-26 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-02-26 (date) — Filing date
- Coral Gables, FL (location) — Company headquarters
- Agamree (product) — Product mentioned in relation to royalty amounts
- Fycompa (product) — Product mentioned in relation to U.S. Rights
FAQ
What were the total sales revenues for Catalyst Pharmaceuticals in the fiscal year ending December 31, 2024?
The filing indicates sales revenue net for the period, but specific total dollar amounts for FY 2024 are not explicitly stated in the provided snippet. Further review of the full 10-K document is required.
What is the company's primary business address?
The company's business address is 355 Alhambra Circle, Suite 801, Coral Gables, FL 33134.
What is the Central Index Key (CIK) for Catalyst Pharmaceuticals, Inc.?
The Central Index Key for Catalyst Pharmaceuticals, Inc. is 0001369568.
What is the Standard Industrial Classification (SIC) code for Catalyst Pharmaceuticals?
The Standard Industrial Classification code for Catalyst Pharmaceuticals is 2834, which corresponds to Pharmaceutical Preparations.
What is the filing date of this 10-K report?
This 10-K report was filed on February 26, 2025.
From the Filing
0000950170-25-027714.txt : 20250226 0000950170-25-027714.hdr.sgml : 20250226 20250226160535 ACCESSION NUMBER: 0000950170-25-027714 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 105 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250226 DATE AS OF CHANGE: 20250226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CATALYST PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001369568 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33057 FILM NUMBER: 25669962 BUSINESS ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: (305) 529-2522 MAIL ADDRESS: STREET 1: 355 ALHAMBRA CIRCLE STREET 2: SUITE 801 CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST PHARMACEUTICAL PARTNERS, INC. DATE OF NAME CHANGE: 20110215 FORMER COMPANY: FORMER CONFORMED NAME: Catalyst Pharmaceutical Partners, Inc. DATE OF NAME CHANGE: 20060719 10-K 1 cprx-20241231.htm 10-K 10-K FY false 0001369568 three year five year five year http://catalystpharma.com/20241231#PresidentAndChiefExecutiveOfficerMember 6 years http://fasb.org/us-gaap/2024#LiabilitiesCurrent http://fasb.org/us-gaap/2024#LiabilitiesCurrent 0001369568 cprx:AgamreeMember cprx:RoyaltyMoreThanTwoBillionMember 2024-01-01 2024-12-31 0001369568 cprx:AgamreeMember cprx:RoyaltyMoreThanHundredMillionAndLessThanTwoHundredMillionMember 2024-01-01 2024-12-31 0001369568 srt:MaximumMember 2024-01-01 2024-12-31 0001369568 cprx:U.s.RightsForFycompaMember 2024-12-31 0001369568 us-gaap:SalesRevenueNetMember cprx:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001369568 us-gaap:SoftwareDevelopmentMember 2024-12-31 0001369568 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001369568 cprx:U.s.RightsForFycompaMember cprx:RoyaltyMoreThanTenMillionAndLessThanHundredMillionMember us-gaap:RoyaltyAgreementTermsMember srt:MaximumMember 2024-01-01 2024-12-31 0001369568 cprx:U.s.RightsForFycompaMember cprx:RoyaltyMoreThanHundredAndTwentyFiveMillionMember 2024-01-01 2024-12-31 0001369568 us-gaap:SalesRevenueNetMember cprx:CustomerAMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001369568 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-12-31 0001369568 cprx:LicenseAgreementWithBioMarinMember 2024-01-01 2024-12-31 0001369568 cprx:RoyaltyMoreThanFiveHundredMillionAndLessThanSevenHundredFiftyMillionMember cprx:AgamreeMember srt:MaximumMember 2024-01-01 2024-12-31 0001369568 us-gaap:SalesRevenueNetMember cprx:CustomerBMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001369568 2023-12-31 0001369568 us-gaap:RetainedEarningsMember 2023-12-31 0001369568 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001369568 srt:MinimumMember cprx:AgamreeMember cprx:RoyaltyMoreThanTwoBillionMember 2024-01-01 2024-12-31 0001369568 cprx:ProductRevenueNetMember 2024-01-01 2024-12-31 0001369568 cprx:KyePharmaceuticalsMember us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-12-31 0001369568 srt:MinimumMember cprx:RoyaltyMoreThanTwoHundredMillionAndLessThanThreeHundredMillionMember cprx:AgamreeMember 2024-01-01 2024-12-31 0001369568 cprx:VamoroloneMember 2023-07-01 2023-07-31 0001369568 cprx:RoyaltyMoreThanHundredMillionAndLessThanHundredAndTwentyFiveMillionMember cprx:U.s.RightsForFycompaMember srt:MinimumMember us-gaap:RoyaltyAgreementTermsMember 2024-01-01 2024-12-31 0001369568 cprx:LicenseAndAcquiredIntangiblesForFycompaMember 2024-01-01 2024-12-31 0001369568 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001369568 cprx:FirdapseMember 2023-01-01 2023-12-31 0001369568 srt:MinimumMember cprx:LicenseAgreementWithBioMarinMember 2024-01-01 2024-12-31 0001369568 us-gaap:EmployeeStockOptionMember srt:MaximumMemb